Houston-based LogoBar has created an advertising model that doesn't annoy the viewers. Getty Images

Steven Jones knows people dislike ads. Actually, he reasons, it's less that they dislike ads, but more that they don't like having those ads interrupt what they're doing.

"They want to be in control of their experience," he says. "And we've nearly always had things that allow consumers to skip ads – the remote control, where you could change the channel; now there are DVRs that let you skip them. That's all about control."

Jones knows, however, that consumers do want the information ads contain. And he thinks one of the best ways to give that to them in this splintered and ever-changing media environment is for advertisers to concede that concept of audience control. That's what LogoBar aims to do. Where a traditional commercial on television or before an online video might be 15 or 30 seconds, LogoBar features a company's logo or a product it's selling at the bottom of the video. The ad or logo will also appear when the viewer hits pause (or some other engagement) on the video. The viewer, if interested in the product can then choose to engage with it by clicking on the offer that's being advertised or on the product itself, which would then take that viewer to the advertiser's site.

The goal, says Jones, is two-fold: get the products and services in front of potential buyers, and allow those buyers to be the ones who determine if they want to engage.

"It's not intrusive at all," says Jones about the concept. "It allows a brand to be seen, which can spur interest. But keeping control in the hands of the intended audience is the key. This allows advertisers to think about their brands as a call to action. And this method of delivery aligns with the experience the viewer is already having."

Jones realizes that many people view ads as interruptions. He says that one of the reasons Google began making three-second ads right about 2015 was to capture on the shortening attention span of viewers who, he says studies show, were looking to skip ads the second they appeared.

LogoBar created digital technology that allows its clients to create its own ads. LogoBar installs the tech and then the client's team can build on it. But LogoBar can also create the advertising from end to end as well. The tech plugins work across multiple platforms including Brightcove, Kaltura, Flowplayer, and native iOS/Android players. By building that compatibility into its technology, Jones says that LogoBar can be easily and widely used.

"I think of us as still being an early startup," he says of the company. "But we have a strong team of five here, and I see us growing the business and the team across the next few years."

LogoBar has worked with ESPN+ and other local and national clients. And he believes LogoBar is poised to create what thinks of as a win-win for consumers and advertisers alike.

"Firms are still creating 30, 60-second 'stories' in their ads. Those aren't going to go away. And people will watch them – when they want to, on their own time. What we're offering is something that complements traditional advertising and gives consumers both an interactive experience and control over their viewing and time."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Nominations are now open for the 2025 Houston Innovation Awards

Calling All Innovators

Calling all Houston innovators: The Houston Innovation Awards return this fall to celebrate the best and brightest in the Houston innovation ecosystem right now.

Presented by InnovationMap, the fifth annual Houston Innovation Awards will take place November 5 at TMC Helix Park.

The awards program will honor the top startups and innovators in Houston across 10 categories, and we're asking you to nominate the most deserving Houston innovators and innovative companies today.

This year's categories are:

  • Minority-founded Business, honoring an innovative startup founded or co-founded by BIPOC or LGBTQ+ representation.
  • Female-founded Business, honoring an innovative startup founded or co-founded by a woman.
  • Energy Transition Business, honoring an innovative startup providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy, and beyond.
  • Health Tech Business, honoring an innovative startup within the health and medical technology sectors.
  • Deep Tech Business, honoring an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics, and space sectors.
  • Startup of the Year (People's Choice), honoring a startup celebrating a recent milestone or success. The winner will be selected by the community via an interactive voting experience.
  • Scaleup of the Year, honoring an innovative later-stage startup that's recently reached a significant milestone in company growth.
  • Incubator/Accelerator of the Year, honoring a local incubator or accelerator that is championing and fueling the growth of Houston startups.
  • Mentor of the Year, honoring an individual who dedicates their time and expertise to guide and support budding entrepreneurs.
  • Trailblazer, honoring an innovator who's made a lasting impact on the Houston innovation community.

Nominations may be made on behalf of yourself, your organization, and other leaders in the local innovation scene. The nomination period closes on August 31, so don't delay — nominate today at this link, or fill out the embedded form below.

Our panel of esteemed judges will review the nominations, and determine the finalists and winners. Finalists will be unveiled on September 30, and the 2025 Houston Innovation Awards winners will be announced live at our event on November 5.

Tickets will go on sale this fall. Stay tuned for that announcement, as well as more fanfare leading up to the 2025 Houston Innovation Awards.

Nominate now:

Interested in Innovation Awards sponsorship opportunities? Please contact sales@innovationmap.com.

MD Anderson launches $10M collaboration to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have announced a strategic collaboration to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The collaboration will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."